. Kaplan-Meier plot of incidence probability of keratoconus in patients with AD and control subjects. There was no statistically significant difference in the incidence probability of keratoconus between the AD and control groups (0.01% and 0.04% at 10 years, respectively [P ¼ .16, log-rank test]).
Risk of thromboembolic events in patients treated with thalidomide for cutaneous lupus erythematosus: A multicenter retrospective study To the Editor: Thalidomide (ie, -N-phthalimido glutarimide) has shown efficacy in treating severe cutaneous lupus erythematosus (CLE). However, its efficacy needs to be balanced against the potential adverse events, including thromboembolic events (TEs), which might be life-threatening. 1 The pooled-rate of TEs has been estimated to be 2% (95% confidence interval [CI] 1%-3%). 1 However, clinical and biologic factors associated with the risk for TEs remain unknown. This multicenter, retrospective observational study included histologically confirmed CLE patients treated with thalidomide in 5 dermatology departments of French university hospitals during 1992-May 2017. We recorded all TEs occurring during thalidomide treatment and assessed the risk for TEs by 100 patient-years. Moreover, we sought to identify clinical and biologic factors associated with the risk for TEs considering antiphospholipid antibodies (aPL) or antiphospholipid syndrome (APS) status, starting dose of thalidomide, associated treatments, and cardiovascular risk factors. Kaplan-Meier survival curves, log-rank tests, and Cox proportional hazards regression were performed to assess risk factors for TEs.
Among the 139 included patients (Table I) , 114 (82%) were women. Median age at initiation of thalidomide was 38 (range 11-79) years. Before thalidomide initiation, 19 (13.6%) had significant titers of aPL. Moreover, 6 (4.3%) had APS. In all, 8 spontaneous TEs were recorded during thalidomide treatment in 8 patients. The risk for overall thrombosis was 2.74 for 100 patient-years, and the risk for arterial thrombosis Fig 1, B) . The risk was lower for patients with a starting thalidomide dose of 50 mg/day than those with a starting thalidomide dose of 100 mg/day or higher (HR 0.23, 95% CI 0.005-0.96; P ¼ .04; Fig 1, C ) and for those who received hydroxychloroquine and thalidomide (HR 0.14, 95% CI 0.02-0.85; P ¼ .03; Fig 1, D) . The risk for TEs did not significantly differ among patients with APS or significant aPL titers, by smoking status, or for those receiving low-dose aspirin or systemic corticosteroids (data not shown). The risk for arterial thrombosis was higher for active smokers (P ¼ .02), patients with hypercholesterolemia (P ¼ .023), and patients with a history of arterial thrombosis (P ¼ .012). Among the limitations of this study is the retrospective design. Moreover, TEs were rare events in the study cohort; therefore, no statistical analyses were performed to assess the risk factors for venous thrombosis and the impact of diabetes mellitus. Overall, we found a substantial risk for TEs among CLE patients treated with thalidomide that was estimated to be 2.74 thromboses/100 patient-years. A higher risk for TEs among patients with aPL treated with thalidomide has been suggested in small case series. 2 Moreover, aPL was an exclusion criteria in a recent study of CLE patients treated with thalidomide.
3 Although no conclusion can be made regarding the retrospective design, we did not confirm a higher risk among patients with APS or significant aPL titers.
We therefore suggest that thalidomide can be used in severe antimalarial-resistant CLE, even if the patient has significant aPL titers. We recommend a starting dose of 50 mg/day of thalidomide in association with hydroxychloroquine. It is not certain whether low-dose aspirin prevents TEs in thalidomide-treated CLE patients. However, low-dose aspirin has shown an ability to prevent the first TE in lupus patients with aPL 4,5 and should be used at least in this population. To the Editor: High neutrophil-to-lymphocyte ratio (NLR) before starting cytotoxic T-lymphocytee associated antigen 4 antibody ipilimumab was previously found associated with improved overall survival (OS) in patients with metastatic melanoma.
1,2
We examined whether high NLR is an independent risk factor for poor OS in patients receiving programmed cell death 1 (PD1) antibodies nivolumab or Table I . Main characteristics of the 101 patients with melanoma
